Skip to main content
. 2021 Jul 12;4:859. doi: 10.1038/s42003-021-02375-9

Fig. 6. Depletion of B cells results in loss of efficacy in mice treated with FEC + oHSV-1.

Fig. 6

a C57/Bl6 mice bearing E0771 tumors were treated with either an anti-CD20 antibody or isotype antibody, followed by treatment with saline, FEC, oHSV-1, CP, FEC + oHSV-1, or FEC + oHSV-1 + CP therapy. *Created using BioRender.com. b Tumor volumes were measured every 2–3 days from the start of treatment until mice reached endpoint. Each line represents individual mice within the group. c Kaplan–Meier survival curves of combination therapy treatments, with both the depletion and isotype antibodies. d Flow cytometry confirmed that a singular dose of an anti-CD20 antibody is sufficient to deplete B cells within 24 h of administration. e Bar plot showing IgG production levels from naïve mice, tumor-bearing mice, and therapeutically treated mice. *Mantel–Cox test was used for statistical analyses in c, two-tailed paired t test was used for statistical analyses in d, and two-tailed unpaired t test was used for statistical analyses in e. Error bars are representative of the standard deviation.